U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
OpenAI Hires OpenClaw Creator Peter Steinberger to Advance Next-Generation AI Agents 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
CAMBRIDGE, Mass., April 24, 2018 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2018 financial results and business highlights.
| What: | Vericel Corporation First-Quarter 2018 Earnings Call | |
| When: | Tuesday, May 8, 2018 at 8:30am (EDT) | |
| Where: | http://investors.vcel.com/events-presentations | |
| How: | The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events-presentations. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. |
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation first-quarter 2018 earnings call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events-presentations until May 8, 2019. A replay of the call will also be available until 11:30am (EDT) on May 13, 2018 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 1564056.
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
VCEL-fin
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
Solebury Trout
[email protected]
+1 (646) 378-2947
Lee Stern
Solebury Trout
[email protected]
+1 (646) 378-2922
